Clinuvel公司的7月份newsletter提到的白癜风部分！

thefirstdone

VITILIGO
An update on the vitiligo program globally, including Singapore, is forthcoming as soon as the first data analysis has been released to our teams. The trio of data sets, patients’ experiences and physicians’ assessment has driven Clinuvel’s decisi** in clinical development, and the same approach is being applied to our vitiligo program.
Vitiligo is a field of increasing scientific attention. The innovation of introducing SCENESSE® has been central in some of this year’s key dermatology conferences. In early June the World Congress of Dermatology took place in Vancouver, and clinical results of Clinuvel’s US program (CUV102) were presented by a number of leading physicians in the field. The feedback remains strongly positive and our interchange with the medical community will need to lead to a concerted approach to propose an acceptable treatment in major markets.

thefirstdone

我E文不行。求大神翻译。
新加坡的前期数据分析，依据病人的体验，医生的评估，在临床进展上要做一些改进。同时把这些方法应用于白癜风的研究里。
白癜风越来越被科学界关注， 公司的SCENESSE药在今年的很多关键皮肤病会议上被关注到。6月份温哥华的世界皮肤病大会上，知名有影响力的医生提到了在美国的CUV102研究（早期SCENESSE药在美国的临床试验），反响都是积极的，公司做一些改变，形成一个可接受的治疗方法，满足主要市场上的要求。

thefirstdone

新加坡的结果是不是出来了

thefirstdone

我是这样臆测的。
这个药是直接在皮下促进黑色素细胞生长的，结合现有的免疫抑制的药（他克莫司，托法替尼之类的），一边抑制T细胞攻击黑色素细胞，一边直接促进黑色素细胞生长，说不定是未来治疗的方向。
这些是现成上市的药，有可能在未来几年内快速组合变成新的疗法

回忆中

不知道还要等多久

亦宁

目前所知道的信息，SCENESSE只是刺激α-MSH 促进黑色素生成的药物之一，有可能属于主治EPP病，对白癜风有一定辅助疗效的药物，类似普特彼他克莫司软膏的研发成果应用。期待更多临床实践的数据了！